Francesco Pettini

Ms. Francesco Pettini

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FPFrancesco Pettini
Francesco Pettini
AVAnna Visibelli
Anna Visibelli
VCVittoria Cicaloni
Vittoria Cicaloni
DIDaniele Iovinelli
Daniele Iovinelli
OSOttavia Spiga
Ottavia Spiga
In this review, we focus on bioinformatic oncology as an integrative discipline that incorporates knowledge from the mathematical, physical, and computational fields to further the biomedical understanding of cancer. Before providing a deeper insight into the bioinformatics approach and utilities involved in oncology, we must understand what is a system biology framework and the genetic connection, because of the high heterogenicity of the backgrounds of people approaching precision medicine. In fact, it is essential to providing general theoretical information on genomics, epigenomics, and transcriptomics to understand the phases of multi-omics approach. We consider how to create a multi-omics model. In the last section, we describe the new frontiers and future perspectives of this field.

13 December 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
FPFrancesco Pettini
Francesco Pettini
Carmen DomeneCarmen Domene
Carmen Domene
SFSimone Furini
Simone Furini

1 July 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
PLPietro Enea Lazzerini
Pietro Enea Lazzerini
ACAlessandra Cartocci
Alessandra Cartocci
YQYongxia Sarah Qu
Yongxia Sarah Qu
Simona SaponaraSimona Saponara
Simona Saponara
SFSimone Furini
Simone Furini
MBMohamed Boutjdir
Mohamed Boutjdir
Background - Worldwide, there are millions of chronic proton pump inhibitors (PPIs) users, often without a compelling indication. Evidence indicates that PPI treatment can increase mortality, in part due to a higher risk of QTc-related malignant arrhythmias. Drug-induced hypomagnesemia is currently believed to be the underlying mechanism, and therefore serum magnesium monitoring is recommended to minimize arrhythmic risk. However, recent data suggest that PPIs might also directly interfere with cardiac electrophysiology. To test this hypothesis, a translational study was performed using a combination of electrophysiology, molecular dynamics simulations, and population data. Methods - First, the effect of different PPIs on the ether-a-go-go-related-gene potassium channel (hERG) current was evaluated in HEK293-cells expressing hERG. Then, free energy calculations were performed to investigate the binding of these drugs to hERG. Finally, the impact of PPIs on the risk of QTc prolongation was assessed in a retrospective observational cohort of 3867 US Veterans, including 1289 PPI-treated subjects. Results - Clinically-relevant concentrations of different PPIs induced a significant inhibition of the hERG-current in-vitro, pantoprazole and lansoprazole being the most potent compounds. Atomic simulations demonstrated that such a blocking class-effect is likely due to direct PPIs binding to hERG-channel pore cavity. Accordingly, in a US Veterans cohort, PPI treatment was independently associated with a ~20-40% increased risk of QTc prolongation, also regardless of hypomagnesemia. Moreover, a synergistic interaction between PPIs and most of the traditional QT-prolonging risk factors was demonstrated. Conclusions - Altogether, this study provides, for the first time, strong evidence that PPIs can per se promote QTc prolongation, by directly inhibiting hERG function. A careful evaluation of the benefit/risk ratio is recommended whenever PPIs are administered in subjects with other QT-prolonging risk factors, even in the absence of hypomagnesemia.

27 June 2025 in Nanomedicine
Verified
Journal Article
Closed access
FRFrancesca Re
Francesca Re
SPSara Pelucchi
Sara Pelucchi
FPFrancesco Pettini
Francesco Pettini
APAntonella Prantera
Antonella Prantera
FTFabiola Troisi
Fabiola Troisi
DBDonatella Barisani
Donatella Barisani
This review explores the recent advancements in nanodelivery systems designed to improve intestinal delivery, focusing on inflammatory bowel diseases (IBDs) and colorectal cancer (CRC). It outlines the challenges associated with conventional drug therapies, including poor bioavailability, systemic side effects, and nonspecific targeting, which often limit therapeutic outcomes. Nanotechnology-based delivery platforms, such as lipid-based or polymeric nanoparticles, offer promising alternatives due to their ability to enhance drug stability, enable site-specific delivery, and reduce toxicity.It highlights how these nanosystems can be engineered to respond to the unique physiological and biochemical conditions of the inflamed gut, such as pH, enzymes, and reactive oxygen species. It also discusses various strategies to achieve active targeting through ligand-receptor interactions, thereby improving the precision of drug delivery to inflamed tissues.Despite the progress, the review notes that challenges remain in translating these technologies into clinical practice. Regulatory hurdles, manufacturing scalability, long-term safety, and the complexity of disease pathogenesis continue to pose significant obstacles. Overall, nanodelivery systems targeting the intestine represent a transformative approach with the potential to significantly improve IBD and CRC management, though further research and development are essential for clinical implementation.

21 June 2022 in Frontiers in Bioinformatics
Verified
Journal Article
Open access
VCVittoria Cicaloni
Vittoria Cicaloni
MKMalancha Karmakar
Malancha Karmakar
LFLuisa Frusciante
Luisa Frusciante
FPFrancesco Pettini
Francesco Pettini
AVAnna Visibelli
Anna Visibelli
OSOttavia Spiga
Ottavia Spiga
The transmembrane glycoprotein CD93 has been identified as a potential new target to inhibit tumor angiogenesis. Recently, Multimerin-2 (MMRN2), a pan-endothelial extracellular matrix protein, has been identified as a ligand for CD93, but the interaction mechanism between these two proteins is yet to be studied. In this article, we aim to investigate the structural and functional effects of induced mutations on the binding domain of CD93 to MMRN2. Starting from experimental data, we assessed how specific mutations in the C-type lectin-like domain (CTLD) affect the binding interaction profile. We described a four-step workflow in order to predict the effects of variations on the inter-residue interaction network at the PPI, based on evolutionary information, complex network metrics, and energetic affinity. We showed that the application of computational approaches, combined with experimental data, allowed us to gain more in-depth molecular insights into the CD93–MMRN2 interaction, offering a platform for developing innovative therapeutics able to target these molecules and block their interaction. This comprehensive molecular insight might prove useful in drug design in cancer therapy.

5 December 2025 in Journal of Molecular Biology
Verified
Journal Article
Closed access
ASAayushi Singh
Aayushi Singh
FPFrancesco Pettini
Francesco Pettini
BGBeatrice Gianibbi
Beatrice Gianibbi
SDSayan Das
Sayan Das
DBDonatella Barisani
Donatella Barisani
VVVincenzo Venditti
Vincenzo Venditti